Multiple Sclerosis

100% of MS patients have prior EBV infection. Molecular mimicry initiates the disease. But whether it establishes a self-sustaining autoimmune attack depends on vitamin D status, gut microbiome, and oxidized lipid burden — all modifiable.

The Initiation — Molecular Mimicry

EBV EBNA1 protein has sequence homology with GlialCAM — a myelin-associated protein. Anti-EBNA1 antibodies (universal after EBV infection) cross-react with GlialCAM in people whose immune tolerance is sufficiently impaired to allow self-reactive antibody production.

The self-reactive antibodies:

• Bind myelin-associated antigens
• Recruit complement and cytotoxic T cells
• Initiate demyelination

Why only some EBV-infected people develop MS:

• Vitamin D status — adequate D3 prevents Th17 differentiation that amplifies the anti-myelin attack
• Gut microbiome — specific dysbiotic patterns consistently precede MS onset by years in prospective studies
• Oxidized lipid burden — microglial efferocytosis failure determines whether the myelin debris antigen pool expands

The Myelin Lipid Composition Problem

Myelin is ~70% lipid by dry weight. When the dietary PUFA fraction is high, polyunsaturated fatty acids incorporate into myelin membranes — increasing oxidative vulnerability. Oxidized myelin lipids are more immunogenic than intact myelin lipids → expand the repertoire of anti-myelin antibodies → more extensive demyelination.

Microglial Efferocytosis — The Same Mechanism

Microglia are the CNS equivalent of peripheral macrophages. MERTK and AXL on microglia perform efferocytosis of myelin debris and apoptotic oligodendrocytes. OXLAMs → MERTK/AXL impairment → failure to clear myelin debris → accumulation of partially degraded myelin presenting citrullinated and oxidized antigens → expanding autoantigen repertoire.

This is efferocytosis failure in the CNS, driven by the same molecular mechanism as peripheral macrophage efferocytosis failure.

Protocol-Specific Additions

Vitamin D3 at therapeutic dose (5000–10000 IU with K2 monitoring):

• Specifically suppresses Th17 differentiation (the T cell subset driving CNS inflammation)
• Directly reduces BBB permeability
• Promotes remyelination (oligodendrocyte precursor cell differentiation)
• Optimal serum level for MS: 60–80 ng/ml (substantially above the conventional "sufficient" 30 ng/ml)

Lion's Mane mushroom (500–1000mg):

• Erinacines cross the BBB and stimulate NGF production in oligodendrocytes
• Directly promotes remyelination through NGF-mediated oligodendrocyte precursor cell differentiation
• Reduces microglial M1 polarization (the activated inflammatory state perpetuating demyelination)
• The only widely accessible natural compound with direct remyelination support evidence

2-Methoxyestradiol (2-ME2) via DIM: The estrogen metabolite promoted by DIM has specific neuroprotective effects:

• Inhibits HIF-1α in activated immune cells infiltrating CNS white matter
• The lesions create local hypoxia → HIF-1α activation in infiltrating T cells → amplified destruction
• 2-ME2 blunts this hypoxic amplification

Connections

• [[Efferocytosis Failure]] — microglial version of the same mechanism
• [[Estrobolome]] — local CNS estrogen metabolism
• [[Oxidized Lipid Cascade]] — myelin lipid composition problem
• [[Phase 2 - Mast Cell Stabilization]] — Th17 suppression via vitamin D
• [[EDS-MCAS-Eczema Cluster]] — shared upstream drivers
• [[Gut Microbiome Ecology]] — dysbiosis preceding MS onset